Following the news of the $3 billion settlement between the government and GlaxoSmithKline for illegal promotion of prescription drugs for unapproved uses, Mr. Goozner say many assume off-label promotion will become a thing of the past. However, he wrote, just because companies are more focused on compliance with the law doesn’t mean they aren’t still promoting the drugs.
Related Articles on Pharmaceuticals:
AMA Adopts New Policy for Drug Shortages
Senate Proposal Would Allow FDA to Fast Track Drugs for Unmet Needs
10 Recent FDA Drug and Medical Device Decisions
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
